FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097501147> ?p ?o ?g. }

• W2097501147 endingPage "348" @default.
• W2097501147 startingPage "340" @default.
• W2097501147 abstract "Background. Sarcopenia is a defining feature of cancer cachexia associated with physical decline, poor quality of life and poor prognosis. Thus, maintaining muscle mass is an important aim of cachexia treatment. Many patients at risk for developing cachexia or with cachexia experience side effects of chemotherapy that might aggravate the development of cachexia. However, achieving tumor control might reverse the catabolic processes causing cachexia. There is limited knowledge about muscle mass changes during chemotherapy or whether changes in muscle mass are associated with response to chemotherapy.Patients and methods. In this pilot study, patients with advanced non-small cell lung cancer (NSCLC) receiving three courses of palliative chemotherapy were analyzed. Muscle mass was measured as skeletal muscle cross sectional area (SMCA) at the level of the third lumbar vertebrae using CT images taken before and after chemotherapy.Results. In total 35 patients, 48% women, mean age 67 years (range 56–86), participated; 83% had stage IV disease and 71% were sarcopenic at baseline. Mean reduction in SMCA from pre- to post-chemotherapy was 4.6 cm2 (CI 95% −7.3–−1.9; p < 0.002), corresponding to a 1.4 kg loss of whole body muscle mass. Sixteen patients remained stable or gained SMCA. Of these, 14 (56%) responded to chemotherapy, while two progressed (p = 0.071). Maintaining or gaining SMCA resulted in longer median overall survival (loss: 5.8 months, stable/gain: 10.7 months; p = 0.073). Stage of disease (p = 0.003), treatment regimen (p = 0.023), response to chemotherapy (p = 0.007) and SMCA change (p = 0.040), but not sarcopenia at baseline, were significant prognostic factors in the multivariate survival analyses.Conclusion. Almost half of the patients had stable or increased muscle mass during chemotherapy without receiving any cachexia treatment. Nearly all of these patients responded to the chemotherapy. Increase in muscle mass, but not sarcopenia at baseline, was a significant prognostic factor." @default.
• W2097501147 created "2016-06-24" @default.
• W2097501147 creator A5040383132 @default.
• W2097501147 creator A5050523412 @default.
• W2097501147 creator A5072249264 @default.
• W2097501147 creator A5076215953 @default.
• W2097501147 creator A5081872063 @default.
• W2097501147 creator A5084228112 @default.
• W2097501147 creator A5088245876 @default.
• W2097501147 date "2014-09-16" @default.
• W2097501147 modified "2023-09-30" @default.
• W2097501147 title "Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer" @default.
• W2097501147 cites W1968626722 @default.
• W2097501147 cites W1974423646 @default.
• W2097501147 cites W2003064100 @default.
• W2097501147 cites W2013072422 @default.
• W2097501147 cites W2019607817 @default.
• W2097501147 cites W2021929534 @default.
• W2097501147 cites W2036610278 @default.
• W2097501147 cites W2040713811 @default.
• W2097501147 cites W2044649768 @default.
• W2097501147 cites W2045022582 @default.
• W2097501147 cites W2053545935 @default.
• W2097501147 cites W2074295444 @default.
• W2097501147 cites W2092361675 @default.
• W2097501147 cites W2097022747 @default.
• W2097501147 cites W2101398993 @default.
• W2097501147 cites W2107089530 @default.
• W2097501147 cites W2118558111 @default.
• W2097501147 cites W2127424726 @default.
• W2097501147 cites W2145280166 @default.
• W2097501147 cites W2148538398 @default.
• W2097501147 cites W2151296885 @default.
• W2097501147 cites W2166399931 @default.
• W2097501147 cites W2167571044 @default.
• W2097501147 cites W2169244250 @default.
• W2097501147 doi "https://doi.org/10.3109/0284186x.2014.953259" @default.
• W2097501147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25225010" @default.
• W2097501147 hasPublicationYear "2014" @default.
• W2097501147 type Work @default.
• W2097501147 sameAs 2097501147 @default.
• W2097501147 citedByCount "155" @default.
• W2097501147 countsByYear W20975011472015 @default.
• W2097501147 countsByYear W20975011472016 @default.
• W2097501147 countsByYear W20975011472017 @default.
• W2097501147 countsByYear W20975011472018 @default.
• W2097501147 countsByYear W20975011472019 @default.
• W2097501147 countsByYear W20975011472020 @default.
• W2097501147 countsByYear W20975011472021 @default.
• W2097501147 countsByYear W20975011472022 @default.
• W2097501147 countsByYear W20975011472023 @default.
• W2097501147 crossrefType "journal-article" @default.
• W2097501147 hasAuthorship W2097501147A5040383132 @default.
• W2097501147 hasAuthorship W2097501147A5050523412 @default.
• W2097501147 hasAuthorship W2097501147A5072249264 @default.
• W2097501147 hasAuthorship W2097501147A5076215953 @default.
• W2097501147 hasAuthorship W2097501147A5081872063 @default.
• W2097501147 hasAuthorship W2097501147A5084228112 @default.
• W2097501147 hasAuthorship W2097501147A5088245876 @default.
• W2097501147 hasBestOaLocation W20975011471 @default.
• W2097501147 hasConcept C121608353 @default.
• W2097501147 hasConcept C126322002 @default.
• W2097501147 hasConcept C141071460 @default.
• W2097501147 hasConcept C143998085 @default.
• W2097501147 hasConcept C2776214593 @default.
• W2097501147 hasConcept C2776256026 @default.
• W2097501147 hasConcept C2776694085 @default.
• W2097501147 hasConcept C2777704314 @default.
• W2097501147 hasConcept C2779959927 @default.
• W2097501147 hasConcept C2781413609 @default.
• W2097501147 hasConcept C71924100 @default.
• W2097501147 hasConcept C90924648 @default.
• W2097501147 hasConceptScore W2097501147C121608353 @default.
• W2097501147 hasConceptScore W2097501147C126322002 @default.
• W2097501147 hasConceptScore W2097501147C141071460 @default.
• W2097501147 hasConceptScore W2097501147C143998085 @default.
• W2097501147 hasConceptScore W2097501147C2776214593 @default.
• W2097501147 hasConceptScore W2097501147C2776256026 @default.
• W2097501147 hasConceptScore W2097501147C2776694085 @default.
• W2097501147 hasConceptScore W2097501147C2777704314 @default.
• W2097501147 hasConceptScore W2097501147C2779959927 @default.
• W2097501147 hasConceptScore W2097501147C2781413609 @default.
• W2097501147 hasConceptScore W2097501147C71924100 @default.
• W2097501147 hasConceptScore W2097501147C90924648 @default.
• W2097501147 hasIssue "3" @default.
• W2097501147 hasLocation W20975011471 @default.
• W2097501147 hasLocation W20975011472 @default.
• W2097501147 hasOpenAccess W2097501147 @default.
• W2097501147 hasPrimaryLocation W20975011471 @default.
• W2097501147 hasRelatedWork W2022565204 @default.
• W2097501147 hasRelatedWork W2047906861 @default.
• W2097501147 hasRelatedWork W2154394704 @default.
• W2097501147 hasRelatedWork W2413020017 @default.
• W2097501147 hasRelatedWork W2575725705 @default.
• W2097501147 hasRelatedWork W2602204300 @default.
• W2097501147 hasRelatedWork W2888816033 @default.
• W2097501147 hasRelatedWork W2894853298 @default.
• W2097501147 hasRelatedWork W3000951850 @default.

• next